UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): October 20,
2010
PHARMATHENE,
INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-32587
|
20-2726770
|
||
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
One Park Place, Suite 450, Annapolis,
Maryland
|
21401
|
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number including area code: (410) 269-2600
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
|
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain
Officers.
|
On October 20, 2010, the Board of
Directors of PharmAthene, Inc. (the “Company”) appointed Eric I. Richman to the
position of President and Chief Executive Officer, effective
immediately. Mr. Richman previously served as the Company’s President
and interim Chief Executive Officer since May 2010 and was its President and
Chief Operating Officer between March and May 2010. Prior to being
appointed President and Chief Operating Officer, Mr. Richman served as the
Company’s Senior Vice President, Business Development and Strategic Planning
since joining then-privately-held PharmAthene in 2003.
In connection with his appointment, Mr.
Richman received an option to purchase 125,000 shares of the Company’s common
stock at an exercise price of $4.20 per share, which was the closing price of
the common stock on the NYSE Amex on the date of grant. The
option, granted under the Company’s 2007 Long-Term Incentive Compensation Plan,
vest in installments of 25% per year, with the first vesting to occur on the
first anniversary of the date of grant.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
PHARMATHENE,
INC.
(Registrant)
|
||
|
Date: October
26, 2010
|
By:
|
/s/
Charles A. Reinhart
III
|
|
Charles
A. Reinhart III
|
||
|
Senior
Vice President and Chief Financial Officer
|
||